{
  "subset": "indication",
  "disease": "Primary ciliary dyskinesia",
  "relation": "indication",
  "gold_drugs": [
    "albuterol",
    "vx-371"
  ],
  "seeds_initial": [
    "Dornase alfa",
    "Azithromycin",
    "N-acetylcysteine",
    "Ceratain",
    "Salbutamol",
    "Prednisone",
    "Montelukast",
    "Fluticasone",
    "Ipratropium",
    "Ranitidine",
    "Albuterol",
    "Terbutaline"
  ],
  "seed_history": [
    [
      "Dornase alfa",
      "Azithromycin",
      "N-acetylcysteine",
      "Ceratain",
      "Salbutamol",
      "Prednisone",
      "Montelukast",
      "Fluticasone",
      "Ipratropium",
      "Ranitidine",
      "Albuterol",
      "Terbutaline"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_dornase_alfa",
          "name": "Dornase alfa"
        },
        "score": 0.67,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "机制支持与风险通路存在冲突"
        ],
        "caveats": [
          "安全性与潜在不良反应需进一步评估"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_azithromycin",
          "name": "Azithromycin"
        },
        "score": 0.56,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "有效机制支持与潜在反应需评估"
        ],
        "caveats": [
          "缺乏长期使用的安全性数据"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_n_acetylcysteine",
          "name": "N-acetylcysteine"
        },
        "score": 0.55,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "稀释机制支持与反应需评估"
        ],
        "caveats": [
          "安全使用与疗效数据匮乏"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_ceratain",
          "name": "Ceratain"
        },
        "score": 0.53,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "相关靶点与通路有一定机制支持"
        ],
        "caveats": [
          "机制有效性仍需探索"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target→Pathway→Disease",
          "reason": "机制与靶点支持，但需检讨风险通路"
        }
      ],
      "remaining_gaps": [
        "风险通路与疗效关系不明确"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "通过补充证据支持风险通路的可靠性"
      },
      {
        "role": "Skeptic",
        "patch": "强调长期安全性与剂量调整方面的数据不足"
      },
      {
        "role": "Explorer",
        "patch": "优先选择机制更为明确且临床证据充分的候选药物"
      }
    ],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Primary ciliary dyskinesia'. Return only names.\n\n# Prior guidance for Explorer:\n- 增加多样化候选药物，特别是在影响机制上，避免重复已有的候选。\n\n# Heuristics:\n- When 针对实施的新药物: then 明确不良反应风险，应纳入持续监测。\n- When 当前候选药物存在风险: then 必须在评估其疗效时，考虑不良表现对治疗的影响。"
}